Clinical-stage biotechnology company developing antibody treatments for inflammatory and autoimmune diseases
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Spyre Therapeutics, Inc. in the last 30 days yet.
The 1 sources with the most insights about Spyre Therapeutics, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Mentioned in connection with an offering; no view on the stock was provided.
The speaker cited approximately $1.1 billion in cash, no debt, and an estimated enterprise value of about $6.8 billion, but gave no clear recommendation; the investment case depends on pipeline and trial progress.
Mentioned in connection with an offering; no view on the stock was provided.
The speaker cited approximately $1.1 billion in cash, no debt, and an estimated enterprise value of about $6.8 billion, but gave no clear recommendation; the investment case depends on pipeline and trial progress.
Other assets that creators frequently mention in the same content as Spyre Therapeutics, Inc..
The most active sources covering Spyre Therapeutics, Inc. (SYRE) on Kazuha are @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Spyre Therapeutics, Inc. (SYRE) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Spyre Therapeutics, Inc. (SYRE) most frequently also discuss META, SNDK, ASML, AMD, MU. See the "Discussed alongside" section above for full asset pages.